Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, LSK BioPartners is raising $19,999,980.00 in a new round of investment. Sources indicate as part of senior management President, Sung Kim played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LSK BioPartners

LSK BioPartners, Inc is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco,Pangyo, and South Korea). LSK BioPharma specializes in clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea. To learn more about LSK BioPartners, visit http://www.lskbiopharma.com/

Contact:
Sung Kim, President
801-303-7440
sungkim@lskbiopharma.com
https://www.linkedin.com/in/sungchul-kim-096452a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved